MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors
Authors
Naumov, G.Dulloo, S.
Fennell, D.
Lord, S.
Thistlethwaite, Fiona
Maskell, N.
Popat, S.
Blyth, K.
Szlosarek, P.
Aujayeb, A.
Franks, K.
Herrero, Julio
Cunniff, B.
Duncan, J.
Graham, P.
Bexon, A.
Spicer, J.
Affiliation
The Christie NHS Foundation Trust, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Naumov G, Dulloo S, Fennell D, Lord S, Thistlethwaite F, Maskell N, et al. MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S56-S. PubMed PMID: WOS:001345547300130. English.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.114658Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.114658Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114658